A Phase II Trial of Trifluridine/Tipiracil in Combination with Cetuximab Rechallenge in Patients with RAS Wild-Type mCRC Refractory to Prior Anti-EGFR Antibodies: WJOG8916G Trial
1. 系统已在2026-01-02 16:52:51对应助文件进行删除
2. 如有需要请重新发布求助信息
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI: 10.1007/s11523-023-00963-9
文献链接: https://link.springer.com/10.1007/s11523-023-00963-9
其他信息:
出版社: Springer Science and Business Media LLC
作者: Naoki Izawa; Toshiki Masuishi; Naoki Takahashi; Hirokazu Shoji; Yoshiyuki Yamamoto; Toshihiko Matsumoto; Keiji Sugiyama; Takeshi Kajiwara; Kentaro Kawakami; Naoki Aomatsu; Chihiro Kondoh; Hisato Kawakami; Naoki Takegawa; Taito Esaki; Mototsugu Shimokawa; Kazuto Nishio; Yukiya Narita; Hiroki Hara; Yu Sunakawa; Narikazu Boku; Toshikazu Moriwaki; Takako Eguchi Nakajima; Kei Muro
全文下载地址: https://link.springer.com/content/pdf/10.1007/s11523-023-00963-9.pdf
